NCT00151684|CompletedPhase 2
Loading search results
Sponsor study identifier
interventional
25
1 country
1
Study Start
November 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedThe purpose of this study is to explore diazoxide efficacy in treatment of obese men and assessment of maximal insulin suppression in obese men without hyperglycaemia. Obesity is associated with markedly elevated plasma insulin levels throughout the day. The concept is that obese subjects predominantly develop lean tissue resistance against the glucoregulatory actions of insulin, but remain relatively sensitive to the lipogenic and antilipolytic effects of insulin in adipose tissue. According to this theory, suppression of hyperinsulinism by diazoxide, a well known inhibitor of glucose stimulated insulin secretion, might be useful to treat obesity because it will help to reverse the process of lipid storage.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2004
Date type not reportedThis date has not been verified as actual or estimated.
September 8, 2005
Actual (reported)September 9, 2005
Actual (reported)body weight
abdominal circumference
body composition measured by Dual Energy X-ray Absorptiometry
glucose tolerance
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Rijnstate Hospital
Arnhem, Netherlands
Schreuder T, Karreman M, Rennings A, Ruinemans-Koerts J, Jansen M, de Boer H. Diazoxide-mediated insulin suppression in obese men: a dose-response study. Diabetes Obes Metab. 2005 May;7(3):239-45. doi: 10.1111/j.1463-1326.2004.00449.x.
Hans de Boer, MD PhD
Rijnstate Hospital, Arnhem, The Netherlands
First Submitted
September 8, 2005
First Posted
September 9, 2005
Study Start
November 2004
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
February 29, 2008
Record last verified: 2008-02
The Effect of 5-Hydroxytryptophan (5-HTP) on Satiety
Contact the study team to confirm eligibility.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: